Literature DB >> 7356684

Urinary kallikrein excretion in essential and mineralocorticoid hypertension.

O B Holland, J M Chud, H Braunstein.   

Abstract

Urinary kallikrein excretion has been reported to be decreased in patients with essential hypertension and elevated in patients with primary aldosteronism as a reflection of mineralocorticoid activity. Low renin essential hypertension (LREH) has been postulated to result from excess production of an unknown mineralocorticoid(s). Urinary kallikrein excretion was compared in outpatients with essential hypertension, mineralocorticoid hypertension (primary aldosteronism and 17alpha-hydroxylase deficiency), and in normal subjects of the same race. No significant difference in urinary kallikrein excretion of patients with LREH vs. normal renin essential hypertension (NREH) was found for either black (4.1+/-0.4 vs. 4.8+/-0.5 esterase units (EU)/24 h, mean+/-SE, for 27 LREH and 38 NREH, respectively) or white patients (12.2+/-2.3 vs. 11.7+/-1.4 EU/24 h for 13 LREH and 25 NREH, respectively). Urinary kallikrein was decreased in black vs. white hypertensive patients and normal subjects. However, in patients with normal renal function (creatinine clearance >/=80 ml/min) urinary kallikrein was not significantly decreased in either black hypertensive vs. black normal subjects (4.3+/-0.3 vs. 5.4+/-0.6 EU/24 h) or in white hypertensive vs. white normal subjects (11.9+/-1.2 vs. 8.4+/-0.9 EU/24 h). In contrast, hypertensive patients with mild renal insufficiency (creatinine clearance of 41.8+/-78.5 ml/min) had reduced (P < 0.05) urinary kallikrein (3.3 EU/24 h with creatinine clearance of 63.6+/-2.0 for 24 black patients and 4.2+/-0.7 EU/24 h with creatinine clearance of 67.0+/-3.5 for 6 white patients). These results suggest that a reduction in urinary kallikrein excretion rate is an early accompaniment of hypertensive renal injury. Urinary kallikrein excretion in response to a 6-d 10-meq sodium diet and a 3-d Florinef (0.5 mg b.i.d.) administration was compared in hypertensive patients with normal renal function vs. race and age-matched normal subjects. Stimulation of urinary kallikrein excretion by Florinef was equal in black and white normal subjects vs. hypertensive patients (black normals = 12.3+/-2.7 [n = 9], NREH = 11.7+/-1.8 [n = 10], LREH = 10.9+/-1.5 [n = 12]; white normals = 21.2+/-2.9 [n = 11], essential hypertension = 20.9+/-3.2 [10 NREH, 5 LREH]). Stimulation of urinary kallikrein excretion with low sodium diet was decreased (P < 0.05) only in black LREH (black normals = 11.2+/-2.4 [n = 10], NREH = 10.1+/-2.7 [n = 10], LREH = 7.4+/-1.1 [n = 13]; white normals = 19.1+/-2.7 [n = 13], essential hypertension = 17.5+/-2.3 [nine NREH, four LREH]). However, during low sodium diet, black patients with LREH had evidence for less sodium depletion as manifested by a decreased rise in urinary aldosterone excretion (16.3+/-2.7 vs. 33.3+/-6.4 mug/24 h for black normals) and a failure to achieve metabolic balance in 11/13 patients. Thus, the lesser kallikrein stimulation appeared to result from these two factors. Black and white hypertensives with creatinine clearance <80 ml/min had little increase in urinary kallikrein excretion with Florinef or low sodium diet.5 of 12 patients with primary aldosteronism or 17alpha-hydroxylase deficiency did not have an elevated urinary kallikrein excretion rate. Mild renal insufficiency may have contributed to this finding in two of these five patients. Nevertheless, this finding illustrates a limitation to the use of urinary kallikrein excretion rate as an index of mineralocorticoid activity. However, it appears that the majority of patients with LREH have no evidence for excess production of an unknown mineralocorticoid. The failure to find a decrease in urinary kallikrein excretion in racially matched patients with essentil hypertension and normal renal function questions the postulate of a role of the kallikrein-kinin system in the initiation of essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7356684      PMCID: PMC371373          DOI: 10.1172/JCI109678

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  33 in total

1.  EFFECTIVE RENAL BLOOD FLOW IN SUBJECTS WITH ESSENTIAL HYPERTENSION.

Authors:  W Goldring; H Chasis; H A Ranges; H W Smith
Journal:  J Clin Invest       Date:  1941-11       Impact factor: 14.808

2.  Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males.

Authors:  D F DAVIES; N W SHOCK
Journal:  J Clin Invest       Date:  1950-05       Impact factor: 14.808

3.  Urinary kallikrein and plasma renin activity as determinants of renal blood flow. The influence of race and dietary sodium intake.

Authors:  S B Levy; J J Lilley; R P Frigon; R A Stone
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

4.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

5.  Relation between urinary kallikrein and renal function, hypertension, and excretion of sodium and water in man.

Authors:  A Adetuyibi; I H Mills
Journal:  Lancet       Date:  1972-07-29       Impact factor: 79.321

6.  17-hydroxylation deficiency in man.

Authors:  E G Biglieri; M A Herron; N Brust
Journal:  J Clin Invest       Date:  1966-12       Impact factor: 14.808

7.  Saline suppression of plasma aldosterone in hypertension.

Authors:  D C Kem; M H Weinberger; D M Mayes; C A Nugent
Journal:  Arch Intern Med       Date:  1971-09

8.  Altered urinary kallikrein excretion in rats with hypertension.

Authors:  H S Margolius; R Geller; W De Jong; J J Pisano; A Sjoerdsma
Journal:  Circ Res       Date:  1972-03       Impact factor: 17.367

9.  Urinary kallikrein in normal renin essential hypertension.

Authors:  W J Lawton; A E Fitz
Journal:  Circulation       Date:  1977-11       Impact factor: 29.690

10.  Effect of spironolactone on urinary kallikrein excretion in patients with essential hypertension and in primary aldosteronism.

Authors:  M Seino; K Abe; Y Sakurai; N Irokawa; M Yasujima; S Chiba; Y Otsuka; K Yoshinaga
Journal:  Tohoku J Exp Med       Date:  1977-02       Impact factor: 1.848

View more
  14 in total

1.  Evidence for environmental familiality of kallikrein excretion in Utah kindreds.

Authors:  M M Dadone; J B Smith; D L Anderton; K O Ash; R R Williams
Journal:  West J Med       Date:  1986-05

2.  Black/white differences in response to antihypertensive therapy.

Authors:  B J Materson
Journal:  J Natl Med Assoc       Date:  1985-05       Impact factor: 1.798

3.  Recent pathogenic aspects in essential hypertension and hypertension associated with diabetes mellitus.

Authors:  P Weidmann
Journal:  Klin Wochenschr       Date:  1980-10-01

4.  Localization of kallikrein-like activity along a single nephron in rabbits.

Authors:  K Tomita; H Endou; F Sakai
Journal:  Pflugers Arch       Date:  1981-01       Impact factor: 3.657

5.  The effects of propranolol or atenolol on the cardiovascular responses to central hypovolaemia in Europeans and Bengalees.

Authors:  M A Rahman; T Bennett
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

6.  Tissue kallikrein synthesis and its modification by testosterone or low dietary sodium.

Authors:  D H Miller; J Chao; H S Margolius
Journal:  Biochem J       Date:  1984-02-15       Impact factor: 3.857

Review 7.  Treatment of hypertension in black patients with angiotensin-converting enzyme inhibitors.

Authors:  N B Shulman
Journal:  J Natl Med Assoc       Date:  1988-03       Impact factor: 1.798

8.  Chronic kinin receptor blockade induces hypertension in deoxycorticosterone-treated rats.

Authors:  P Madeddu; V Anania; P P Parpaglia; M P Demontis; M V Varoni; M C Fattaccio; N Glorioso
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

Review 9.  The kallikrein-kinin system as a regulator of cardiovascular and renal function.

Authors:  Nour-Eddine Rhaleb; Xiao-Ping Yang; Oscar A Carretero
Journal:  Compr Physiol       Date:  2011-04       Impact factor: 9.090

10.  Changes in urinary kallikrein excretion and plasma natriuretic factor in a patient with primary aldosteronism with special reference to adrenal histology.

Authors:  S Hayami; T Nakada; H Kakizaki; T Yagisawa; H Kaneko; Y Iijima; H Obata; M Miura
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.